We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway.
- Authors
Sharyo S; Yokota-Ikeda N; Mori M; Kumagai K; Uchida K; Ito K; Burne-Taney MJ; Rabb H; Ikeda M
- Abstract
Statins are known to lessen the severity of renal ischemia-reperfusion injury. The present study was undertaken to define the mechanism of renoprotective actions of statins using a mouse kidney injury model. Treatment of mice with pravastatin, a widely used statin, improved renal function after renal ischemia-reperfusion without lowering the plasma cholesterol level. Administration of pravastatin with mevalonate, a product of HMG-CoA reductase, eliminated renal protection suggesting an effect of pravastatin on mevalonate or its metabolism. In hypercholestrolemic apolipoprotein E knockout mice with reduced HMG-CoA reductase activity; the degree of injury was less severe than in control mice, however, there was no protective action of pravastatin on renal injury in the knockout mice. Treatment with a farnesyltransferase inhibitor (L-744832) mimicked pravastatin's protective effect but co-administration with the statin provided no additional protection. Both pravastatin and L-744832 inhibited the injury-induced increase in plasma IL-6 concentration to a similar extent. Our results suggest the protective effect of pravastatin on renal ischemia-reperfusion injury is mediated by inhibition of the mevalonate-isoprenoid pathway independent of its lipid lowering action.
- Publication
Kidney International, 2008, Vol 74, Issue 5, p577
- ISSN
0085-2538
- Publication type
Journal Article
- DOI
10.1038/ki.2008.210